Pfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDA

The US FDA has started processing a week-based growth hormone from partners Pfizer and Opko, which will compete against new drugs from Novo Nordisk and Ascendis.

Danish pharmaceutical companies Novo Nordisk and Ascendis have renewed competition to look forward to in the market for treating dwarfism.

Pfizer announces in a press release that the US Food and Drug Administration has accepted for filing the initial Biologics License Application BLA for somatrogon, which, much like Novo Nordisk's Sogroya (somapacitan) and Ascendis' Transcon hGH is a weekly treatment for growth hormone deficiency.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs